000294122 001__ 294122
000294122 005__ 20250114153408.0
000294122 0247_ $$2doi$$a10.1093/neuonc/noae186
000294122 0247_ $$2pmid$$apmid:39441704
000294122 0247_ $$2ISSN$$a1522-8517
000294122 0247_ $$2ISSN$$a1523-5866
000294122 0247_ $$2altmetric$$aaltmetric:169590254
000294122 037__ $$aDKFZ-2024-02125
000294122 041__ $$aEnglish
000294122 082__ $$a610
000294122 1001_ $$00000-0002-4317-5770$$aLim-Fat, Mary Jane$$b0
000294122 245__ $$aCentral nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions.
000294122 260__ $$aOxford$$bOxford Univ. Press$$c2025
000294122 3367_ $$2DRIVER$$aarticle
000294122 3367_ $$2DataCite$$aOutput Types/Journal article
000294122 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736865213_12089$$xReview Article
000294122 3367_ $$2BibTeX$$aARTICLE
000294122 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294122 3367_ $$00$$2EndNote$$aJournal Article
000294122 500__ $$aVolume 27, Issue 1, January 2025, Pages 13–32
000294122 520__ $$aAdolescents and young adults (AYAs; ages 15-39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor representation in clinical trials. Brain tumors are the second most common tumor type in AYA, with malignant brain tumors being the most common cause of cancer-related death. The 2021 WHO Classification for central nervous system (CNS) Tumors highlights the importance of integrated molecular characterization with histologic diagnosis in several tumors relevant to the AYA population. In this position paper from the Society for Neuro-Oncology (SNO), the diagnosis and management of CNS tumors in AYA is reviewed, focusing on the most common tumor types in this population, namely glioma, medulloblastoma, ependymoma, and CNS germ cell tumor. Current challenges and future directions specific to AYA are also highlighted. Finally, possible solutions to address barriers in the care of AYA patients are discussed, emphasizing the need for multidisciplinary and collaborative approaches that span the pediatric and adult paradigms of care, and incorporating advanced molecular testing, targeted therapy, and AYA-centered care.
000294122 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294122 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294122 650_7 $$2Other$$aadolescents and young adults
000294122 650_7 $$2Other$$abrain tumors
000294122 650_7 $$2Other$$aprecision medicine
000294122 650_7 $$2Other$$asurvivorship
000294122 7001_ $$00000-0002-3461-7223$$aBennett, Julie$$b1
000294122 7001_ $$aOstrom, Quinn$$b2
000294122 7001_ $$aTouat, Mehdi$$b3
000294122 7001_ $$aFranceschi, Enrico$$b4
000294122 7001_ $$aSchulte, Jessica$$b5
000294122 7001_ $$aBindra, Ranjit S$$b6
000294122 7001_ $$aFangusaro, Jason$$b7
000294122 7001_ $$00000-0002-4918-0167$$aDhall, Girish$$b8
000294122 7001_ $$aNicholson, James$$b9
000294122 7001_ $$00000-0001-6700-5621$$aJackson, Sadhana$$b10
000294122 7001_ $$aDavidson, Tom Belle$$b11
000294122 7001_ $$00000-0002-7893-7982$$aCalaminus, Gabriele$$b12
000294122 7001_ $$aRobinson, Giles$$b13
000294122 7001_ $$aWhittle, James R$$b14
000294122 7001_ $$00000-0003-3894-5053$$aHau, Peter$$b15
000294122 7001_ $$00000-0002-6557-895X$$aRamaswamy, Vijay$$b16
000294122 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b17$$udkfz
000294122 7001_ $$aRudà, Roberta$$b18
000294122 7001_ $$aForeman, Nicholas K$$b19
000294122 7001_ $$aHervey-Jumper, Shawn L$$b20
000294122 7001_ $$aDas, Sunit$$b21
000294122 7001_ $$aDirks, Peter$$b22
000294122 7001_ $$aBi, Wenya Linda$$b23
000294122 7001_ $$aHuang, Annie$$b24
000294122 7001_ $$00000-0002-0412-6255$$aMerchant, Thomas E$$b25
000294122 7001_ $$00000-0002-5693-035X$$aFouladi, Maryam$$b26
000294122 7001_ $$00000-0001-5119-7550$$aAldape, Kenneth$$b27
000294122 7001_ $$aVan den Bent, Martin J$$b28
000294122 7001_ $$aPacker, Roger J$$b29
000294122 7001_ $$aMiller, Julie J$$b30
000294122 7001_ $$00000-0001-6674-0157$$aReardon, David A$$b31
000294122 7001_ $$aChang, Susan M$$b32
000294122 7001_ $$00000-0002-2378-4800$$aHaas-Kogan, Daphne$$b33
000294122 7001_ $$00000-0002-5019-2683$$aTabori, Uri$$b34
000294122 7001_ $$00000-0003-2618-4402$$aHawkins, Cynthia$$b35
000294122 7001_ $$aMonje, Michelle$$b36
000294122 7001_ $$aWen, Patrick Y$$b37
000294122 7001_ $$00000-0002-6832-6539$$aBouffet, Eric$$b38
000294122 7001_ $$00000-0003-0713-6384$$aYeo, Kee Kiat$$b39
000294122 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae186$$gp. noae186$$n1$$p13–32$$tNeuro-Oncology$$v27$$x1522-8517$$y2025
000294122 909CO $$ooai:inrepo02.dkfz.de:294122$$pVDB
000294122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000294122 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294122 9141_ $$y2024
000294122 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000294122 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000294122 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294122 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000294122 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000294122 980__ $$ajournal
000294122 980__ $$aVDB
000294122 980__ $$aI:(DE-He78)B062-20160331
000294122 980__ $$aI:(DE-He78)HD01-20160331
000294122 980__ $$aUNRESTRICTED